Publications by authors named "Nadezhda Shostak"

Background: Patients with chronic thromboembolic pulmonary hypertension (CTEPH) in countries with limited resources have, to date, been poorly represented in registries.

Objective: This work assesses the epidemiology, diagnosis, hemodynamic and functional parameters, and treatment of CTEPH in Russia, Kazakhstan, Turkey, Lebanon, and Saudi Arabia.

Methods: A prospective, cohort, phase IV, observational registry with 3-year follow-up (n = 212) in patients aged ≥ 18 years diagnosed with CTEPH was created.

View Article and Find Full Text PDF

Back pain (BP) due to degenerative disc disease (DDD) is a severe, often disabling condition. The aim of this study was to determine the association between the expression level of proinflammatory cytokines (IL-1β, IL-6, and IL-17), angiogenesis markers (VEGF-A and CD31) in intervertebral disc (IVD) tissue and IVD degeneration in young people with discogenic BP. In patients who underwent discectomy for a disc herniation, a clinical examination, magnetic resonance imaging of the lumbar spine, histological and immunohistochemical analyses of these factors in IVD were performed in comparison with the parameters of healthy group samples (controls).

View Article and Find Full Text PDF

Gout is a systemic disease that is caused by the deposition of monosodium urate crystals in various tissues which leads to inflammation in them. This disease is often misdiagnosed. It leads to the lack of adequate medical care and development of serious complications, such as urate nephropathy and disability.

View Article and Find Full Text PDF

Objective: To compare the 24-hour sustained efficacy and safety of a new tramadol once-daily formulation (tramadol OAD) using Contramid((R)) controlled-release technology with a marketed twice-daily formulation (tramadol BID). PATIENTS, DESIGN AND SETTING: 431 patients with osteoarthritis of the knee were enrolled in this randomised, double-blind, multicentre, parallel study. After titration to optimum dose (range 100-400mg), patients received medication for 12 weeks.

View Article and Find Full Text PDF

Objective: In previous studies, the I1 imidazoline specific agonist rilmenidine effectively lowered office blood pressure (BP) in patients with metabolic syndrome, improved glucose metabolism and did not demonstrate unfavourable effects on plasma lipids. The aim of the present study was to investigate the effects of 12weeks therapy with rilmenidine compared with the ACE inhibitor lisinopril on ambulatory BP, plasma lipid and fasting glucose levels in women with metabolic syndrome.

Research Design: Prospective randomised open-label, blinded end-points study.

View Article and Find Full Text PDF

Background: Membrane structure in metabolic syndrome has not been fully investigated. The aim of our study was to determine the relationship between structural parameters of the erythrocyte membrane and blood pressure, indices of obesity, plasma lipids, and glucose levels in female patients with metabolic syndrome.

Material/methods: In 23 women with metabolic syndrome and 12 control normotensive women, anthropometric indices, blood pressure, and serum lipids were evaluated and an oral glucose tolerance test was performed.

View Article and Find Full Text PDF